Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-11-15
1998-08-11
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 50, 514 51, 536 2623, 536 2626, 536 268, 536 2853, 536 2854, 536 2588, 544242, 544243, A61K 31505, A61K 3170, C07D47300, C07H 1910
Patent
active
057927731
ABSTRACT:
The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV infections in humans.
REFERENCES:
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
Lee et al., "Dioxolane Cytosine Nucleosides as Anti-Hepatitis B Agents," Bioorganic & Medicinal Chem. Letters, 5(17), 2011-2014 (Sep. 7, 1995).
Wilson et al., "The Synthesis and Anti-HIV Activity of Pyrimidine Dioxolanyl Nucleosides," Bioorganic & Medicinal Chem. Letters, 3(2), 169-174 (Feb. 1993).
Kim et al., "Asymmetric Synthesis of 1, 3-Dioxolane-Pyrimidine Nucleosides and Their Anti-HIV Activity," J. Medicinal Chem., 35(11), 1987-1995 (May 29, 1992).
Kim et al., (II), L-.beta.-(2S,4S)-and L-.alpha.-(2S,4R-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships, J. Medicinal Chem., 36(5), 519-528 (Mar. 5, 1993).
Chu et al. (III), "Asymmetric Synthesis of Enantiomerically Pure (-)-(1'R,4'R)-Dioxolane-Thymine and Its Anti-HIV Activity," Tetrahedron Letters, 32(31), 3791-3794 (Jul. 29, 1991).
Choi et al., "In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleosides Analogues," J. American Chem. Soc., 113(24), 9377-9379 (Nov. 20, 1991).
S. Balakrishna Pai, et al., "Inhibition of Hepatitis B Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl-.beta.-L-Arabinofuranosyl Yracil," Antimicrobial Agnets and Chemotherapy, vol. 40, No. 2, Feb. 1996, pp. 380-386.
Gang-Qing Yao, et al., "Inhibition of Epstein-Barr Virus Replication by Novel L-Nucleoside, 2'-Fluoro-5-methyl-.beta.-L-arabinofluranosyluracil," Biochemical Pharmacology, vol. 51, pp. 941-947. 1996, Month of publication data is unavailable.
Cheng Yung-Chi
Chu Chung K.
Qu Fucheng
Coleman Henry D.
Crane L. Eric
Kight John
Siebel R. Neil
University of Georgia Research Foundation
LandOfFree
L-.beta.-dioxolane uridine analog administration for treating Ep does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-.beta.-dioxolane uridine analog administration for treating Ep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-.beta.-dioxolane uridine analog administration for treating Ep will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-389244